TrialJournal of cancer research and clinical oncology2023
Impact of omitting fluorouracil from FOLFIRI plus bevacizumab as second-line chemotherapy for patients with metastatic colorectal cancer.
Yuki Matsubara et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.